When you enter multiple keywords separated by space, your search will contain results that match any of the keywords (OR search).
  • 61 Hits
  • Search Condition : Filter (MeSH = Carcinoma, Non-Small-Cell Lung / genetics)
Species Resource Title
Human and Animal Cells II-18(RCB2093) , PC-14(RCB0446) , RERF-LC-KJ(RCB1313) Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines.
Human and Animal Cells A549 , PC-9(RCB4455) Repression of RhoJ expression promotes TGF-β-mediated EMT in human non-small-cell lung cancer A549cells.
Human and Animal Cells Ba/F3(RCB0805) Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation.
Human and Animal Cells EBC-1(RCB1965) , LK-2(RCB1970) Downregulation of a putative tumor suppressor BMP4 by SOX2 promotes growth of lung squamous cell carcinoma.
Human and Animal Cells LC-2/ad(RCB0440) Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.
Human and Animal Cells A549(RCB0098) , LC-2/ad(RCB0440) , RERF-LC-KJ(RCB1313) MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Human and Animal Cells Ba/F3 Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
Human and Animal Cells PC-9(RCB4455) Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Human and Animal Cells PC-9(RCB4455) Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Human and Animal Cells PC-9(RCB4455) Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.
Human and Animal Cells A549(RCB0098) , LC-2/ad(RCB0440) Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
Human and Animal Cells II-18(RCB2093) A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer.
Human and Animal Cells PC-9(RCB4455) ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
Human and Animal Cells LK-2(RCB1970) , RERF-LC-AI(RCB0444) , EBC-1(RCB1965) , LC-1/sq-SF(RCB0438) Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer.
Human and Animal Cells PC-9(RCB4455) A novel, rapid point-of-care test for lung cancer patients to detect epidermal growth factor receptor gene mutations by using real-time droplet-PCR and fresh liquid cytology specimens.
C.elegans tm2526 , tm2518 Rab8 and Rabin8-Mediated Tumor Formation by Hyperactivated EGFR Signaling via FGFR Signaling.
Human and Animal Cells PC-9(RCB4455) Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
Human and Animal Cells PC-9(RCB4455) Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.
Human and Animal Cells PC-9(RCB4455) Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
Human and Animal Cells PC-14(RCB0446) CAFET algorithm reveals Wnt/PCP signature in lung squamous cell carcinoma.